Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis
Lee YH, Bae SC, Song GG
Archives of medical research · 121 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2012-07-01 · Arch Med Res · vol. 43 · número 5 · págs. 356–362
- Editorial
- Elsevier BV
- Citado
- 197 citas · más que el 72% de estudios similares · 1.3× el promedio de su campo
- Referencias
- 44 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Rheumatoid Arthritis Research and Therapies · Natural Compounds in Disease Treatment
- Palabras clave
- omega-3 polyunsaturated fatty acids, rheumatoid arthritis, tender joint count, swollen joint count, morning stiffness, physical function, dietary supplementation
- MeSH
- humans, arthritis, rheumatoid, pain, fatty acids, omega-3, anti-inflammatory agents, non-steroidal, treatment outcome, randomized controlled trials as topic
3 autores
- Young Ho Lee🇰🇷 · autor de correspondenciaKorea University; Korea University Medical Center
- Sang‐Cheol Bae🇰🇷Hanyang University Seoul Hospital; Hanyang University Medical Center; Hanyang University Hospital for Rheumatic Disease
- Gwan Gyu Song🇰🇷Korea University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
We undertook this study to assess the effects of omega-3 polyunsaturated fatty acids (PUFAs) (administered at ≥2.7 g/day) for a minimum duration of 3 months on clinical outcomes in patients with rheumatoid arthritis (RA).
Methods
The authors surveyed randomized controlled trials (RCTs) that examined the effects of omega-3 PUFAs on clinical outcomes in RA patients using Medline and the Cochrane Controlled Trials Register and by performing manual searches. Meta-analysis of RCTs was performed using fixed and random effects models. Outcomes are presented as standardized mean differences (SMD).
Results
Ten RCTs involving 183 RA patients and 187 placebo-treated RA controls were included in this meta-analysis. The analysis showed that omega-3 PUFAs clearly reduced nonsteroidal anti-inflammatory drug (NSAID) consumption (SMD -0.518, 95% CI -0.915 to -0.121, p = 0.011) without between-study heterogeneity (I(2) = 0%). Tender joint count (SMD -0.214, 95% CI-0.489-0.062, p = 0.128), swollen joint count (SMD -0.170, 95% CI-0.454-0.114, p = 0.241), morning stiffness (SMD -0.224, 95% CI-0.955-0.212, p = 0.221), and physical function (SMD 0.264, 95% CI-0.232-0.724, p = 0.314) showed a trend to improve more in patients treated with omega-3 PUFAs than in placebo-treated controls, but they did not reach statistical significance.
Conclusions
This meta-analysis suggests that the use of omega-3 PUFAs at dosages >2.7 g/day for >3 months reduces NSAID consumption by RA patients. Further studies are needed to explore the clinical and NSAID-sparing effects of omega-3 PUFAs in RA.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.